Summary of project PR000575
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000575. The data can be accessed directly via it's Project DOI: 10.21228/M8BM2Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR000575 |
| Project DOI: | doi: 10.21228/M8BM2Z |
| Project Title: | Mayo Pilot and Feasibility: Targeting Myelin Metabolism to Enhance Recovery of Function after SCI |
| Project Summary: | The loss of myelin, degeneration of the myelin producing oligodendroglia and impaired remyelination are essential features of traumatic spinal cord injury (SCI) that significantly limit patient recovery of function. The lipid rich composition of myelin, including exceptionally high levels of saturated fatty acids, underlie its essential physiological roles, including its structural and signaling properties and electrical insulation of axons to facilitate the conduction of nerve impulses. The myelin sheaths also provide metabolic support to the axons they wrap, and myelin health is therefore essential to the maintenance of axon integrity and function in the brain and spinal cord. The primary goal of this Pilot Proposal to the Mayo Clinic Metabolomics Core is to integrate highly sensitive metabolomics liquid chromatography-tandem mass spectrometry (LC/MS/MS) assays to quantify the lipid composition of the myelin membrane, with our conventional neurobehavioral approaches, enabling us to explore the metabolic basis of new interventions capable of promoting myelin regeneration and restoration of patient function. Metabolomics Core expertise in Magnetic Resonance Spectroscopy (NMR) based evaluation of key metabolites involved in CNS injury and repair (N-acetyl-L-aspartate, choline, myo-inositol, glucose/ glutamine and lactate) will also be applied to strengthen our mechanistic understanding of myelin injury and repair. Specifically, utilizing these innovative approaches we will test a novel hypothesis driven by new preliminary findings that the levels of dietary fatty acids can be optimized alone, or in combination with exercise training, to facilitate myelin regeneration and recovery of neurobehavioral function after injury to the adult spinal cord. In Aim 1, we will determine whether alterations in dietary fat, including saturated fat or omega-3 fatty acids, facilitate restoration of the myelin membrane and metabolite signatures of central nervous system repair after experimental SCI in adult mice. In Aim 2, we will determine whether exercise training alone or in combination with dietary fatty acid supplementation fosters myelin regeneration and recovery of function after experimental SCI. The proposed studies will leverage the expertise of the Mayo Metabolomics Core with that of Dr. Scarisbrick (Mayo) in myelin biology and Dr. Gomez Pinilla (UCLA) in central nervous system plasticity to investigate whether two highly targetable lifestyle variables, that is diet and exercise, can be modulated to improve myelin metabolism and functional recovery after SCI. |
| Institute: | Mayo Clinic |
| Last Name: | Scarisbrick |
| First Name: | Isobel |
| Address: | 200 First St. SW, Rochester, Minnesota, 55905, USA |
| Email: | scarisbrick.isobel@mayo.edu |
| Phone: | 507-284-0124 |
Summary of all studies in project PR000575
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST000792 | Large Untargeted Profiling of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS* | 2021-01-19 | 1 | 136 | Uploaded data (1.3M) |
| ST000793 | Targeted FFA Composition of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 20 | Not available |
| ST000794 | Targeted NEFA Panel of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 20 | Not available |
| ST000795 | Targeted Cholesterol Profiling of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 20 | Not available |
| ST000796 | Targeted Sphingolipids Panel of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 20 | Not available |
| ST000797 | Targeted Galactosyl Sphingolipids Concentrations of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 20 | Not available |
| ST000798 | Targeted Sphinomyelin Panel of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 20 | Not available |
| ST000799 | Targeted TCA Panel of Myelin to Enhance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-01-19 | 1 | 19 | Not available |
| ST000848 | Targeting Myelin NEFA of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000849 | Targeting Myelin FFA Compostion of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000850 | Targeting Myelin Cholesterol of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000851 | Targeting Myelin Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000852 | Targeting Myelin Galactosyl Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000853 | Targeting Myelin Sphinomyelin concentrations of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000854 | Targeted FFA Composition in Kallikrein 6 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 20 | Not available |
| ST000856 | Targeted NEFA in Kallikrein 6 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 20 | Not available |
| ST000857 | Targeted Cholesterol Profiling of Myelin to Enhance Recovery of Function after SCI. Second Set of Samples | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 20 | Not available |
| ST000858 | Targeted Sphingolipids in Kallikrein 6 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 20 | Not available |
| ST000859 | Targeted Galactosyl Sphingolipid Concentration in Kallikrein 6 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 20 | Not available |
| ST000860 | Targeted Sphingomyelin Concentrations in Kallikrein 6 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 20 | Not available |
| ST000861 | Targeting Myelin NEFA in PAR1 and PAR2 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000862 | Targeting Myelin FFA Compostion in PAR1 and PAR2 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000863 | Targeting Myelin Cholesterol in PAR1 and PAR2 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000864 | Targeting Myelin Ceramides in PAR1 and PAR2 Mice after SCI | Mus musculus | Mayo Clinic | MS | 2021-02-17 | 1 | 30 | Not available |
| ST000866 | Large Untargeted Profiling in PAR1 and PAR2 Mice after SCI | Mus musculus | Mayo Clinic | MS* | 2021-02-17 | 1 | 232 | Uploaded data (4M) |
| ST000869 | Large Untargeted Profiling in Kallikrein 6 Mice after SCI | Mus musculus | Mayo Clinic | MS* | 2021-02-17 | 1 | 160 | Uploaded data (1.8M) |
